Iambic Therapeutics, Inc. (IAM)

Profile

https://www.iambic.ai

Iambic Therapeutics, Inc. is a clinical-stage biotechnology and life sciences company developing small-molecule medicines through an AI-driven drug discovery platform. Its molecular superintelligence approach combines proprietary artificial intelligence with automated, scalable chemistry and biology experiments to identify drug candidates, refine their characteristics, and support development across therapeutic areas. The company’s current pipeline includes IAM1363, a selective HER2 inhibitor being evaluated in an early-stage clinical trial for patients with HER2-altered solid tumors, as well as preclinical programs targeting KIF18A and CDK2/4. Iambic also provides technology capabilities centered on molecular design, predictive modeling, and experimental validation, including its Enchant and NeuralPLexer systems. Based in San Diego, California, Iambic operates at the intersection of biotechnology, computational science, and pharmaceutical research. Its business model and platform position it within the growing AI-enabled drug discovery market, where advanced computation and laboratory automation are used to improve the identification and optimization of potential therapeutics.